cno Search Results


90
Croda International Plc detergents
Detergents, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cno/CNO/pmc09417176-141-2-12
Average 90 stars, based on 1 article reviews
detergents - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Novus Biologicals nbp1
Nbp1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cno/CNO+Antibody/pm40827851-58-66-67
Average 93 stars, based on 1 article reviews
nbp1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
ApexBio clozapine-n-oxide cno
Clozapine N Oxide Cno, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cno/cno/pmc11228392-449-0-2
Average 90 stars, based on 1 article reviews
clozapine-n-oxide cno - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Enzo Biochem clozapine-n-oxide
Clozapine N Oxide, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cno/clozapine+n+oxide++cno/bio_rxiv__2020__10__07__328765-318-17-19
Average 90 stars, based on 1 article reviews
clozapine-n-oxide - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Hello Bio Inc water-soluble clozapine-n-oxide cno
Water Soluble Clozapine N Oxide Cno, supplied by Hello Bio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cno/clozapine+n+oxide++cno++dihydrochloride/10__1523_slash_JNEUROSCI__0741___21__2021_ascii32_-106-0-3
Average 90 stars, based on 1 article reviews
water-soluble clozapine-n-oxide cno - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Hello Bio Inc cno hb6149
a Experimental design for pharmacological <t>and</t> <t>chemogenetic</t> experiments targeting the OXT and AVP systems in isolated and trained (IST) and group-housed (GH) rats. ( AAV adeno-associated DREADD virus infusion into the hypothalamic paraventricular (PVN) and supraoptic (SON) nuclei; AVP arginine vasopressin; arrow=drug infusions; FIT female intruder test, IS social isolation, OXT oxytocin, OXTR-A OXT receptor antagonist, SURG surgery, V1aR-A V1a receptor antagonist, WO wash-out). b i.c.v. infusion of OXT (50 ng/5 µl) increased aggression in GH (two-tailed Student’s t test t (19) = 2.46, p = 0.024), c but decreased aggression in IST females ( t (8) = 2.33, p = 0.048, data corresponds to FIT4 and 6). d i.c.v. infusion of V1aR-A (750 ng/5 µl), but not OXTR-A (750 ng/5 µl), blocked the anti-aggressive effects of OXT in IST females (one-way ANOVA followed by Bonferroni F (3,28) = 10.1, p = 0.001). Also, the V1aR-A alone did not affect aggression. Both, e i.c.v. infusion of OXTR-A ( t (28) = 4.96, p < 0.0001) and f i.c.v. AVP (0.1 or 1 ng/5 µl) reduced total aggressive behavior ( F (3,54) = 7.48, p = 0.0003) in IST rats. g Chemogenetic activation of OXT neurons in the PVN and SON increased aggression only in metestrus-diestrus GH rats (two-way ANOVA, factor treatment: F (1,19) = 3.342, p = 0.083; estrous cycle: F (1,19) = 6.68, p = 0.018; treatment × estrous cycle: F (1,19) = 6.45, p = 0.02). h Confirmation of virus infection in the PVN (right) and SON (left). OXT-neurophysin I staining: green; mCherry (virus): red. Scale bars 300 µm. Data are shown as mean+SEM. * p < 0.05; ** p < 0.01; *** p < 0.0001 vs either vehicle or control; e p < 0.05 vs met-diestrus. OXT: GH: n = 9 and 12; IST: n = 9; AVP: n = 18, 9, and 9, respectively; OXTR-A: n = 14 and 15; combination OXT/OXTR-A/V1aR-A: n = 8, 6, 8, 9, and 7, respectively; chemogenetics: n = 6 and 15. Control group consisted of (i) rAAV1/2 <t>OXTpr-mCherry+CNO,</t> no virus infusion + (ii) saline, or (iii) CNO.
Cno Hb6149, supplied by Hello Bio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cno/cno/pmc08131389-314-7-9
Average 90 stars, based on 1 article reviews
cno hb6149 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Hello Bio Inc dreadd ligand clozapine- n- oxide
a Experimental design for pharmacological <t>and</t> <t>chemogenetic</t> experiments targeting the OXT and AVP systems in isolated and trained (IST) and group-housed (GH) rats. ( AAV adeno-associated DREADD virus infusion into the hypothalamic paraventricular (PVN) and supraoptic (SON) nuclei; AVP arginine vasopressin; arrow=drug infusions; FIT female intruder test, IS social isolation, OXT oxytocin, OXTR-A OXT receptor antagonist, SURG surgery, V1aR-A V1a receptor antagonist, WO wash-out). b i.c.v. infusion of OXT (50 ng/5 µl) increased aggression in GH (two-tailed Student’s t test t (19) = 2.46, p = 0.024), c but decreased aggression in IST females ( t (8) = 2.33, p = 0.048, data corresponds to FIT4 and 6). d i.c.v. infusion of V1aR-A (750 ng/5 µl), but not OXTR-A (750 ng/5 µl), blocked the anti-aggressive effects of OXT in IST females (one-way ANOVA followed by Bonferroni F (3,28) = 10.1, p = 0.001). Also, the V1aR-A alone did not affect aggression. Both, e i.c.v. infusion of OXTR-A ( t (28) = 4.96, p < 0.0001) and f i.c.v. AVP (0.1 or 1 ng/5 µl) reduced total aggressive behavior ( F (3,54) = 7.48, p = 0.0003) in IST rats. g Chemogenetic activation of OXT neurons in the PVN and SON increased aggression only in metestrus-diestrus GH rats (two-way ANOVA, factor treatment: F (1,19) = 3.342, p = 0.083; estrous cycle: F (1,19) = 6.68, p = 0.018; treatment × estrous cycle: F (1,19) = 6.45, p = 0.02). h Confirmation of virus infection in the PVN (right) and SON (left). OXT-neurophysin I staining: green; mCherry (virus): red. Scale bars 300 µm. Data are shown as mean+SEM. * p < 0.05; ** p < 0.01; *** p < 0.0001 vs either vehicle or control; e p < 0.05 vs met-diestrus. OXT: GH: n = 9 and 12; IST: n = 9; AVP: n = 18, 9, and 9, respectively; OXTR-A: n = 14 and 15; combination OXT/OXTR-A/V1aR-A: n = 8, 6, 8, 9, and 7, respectively; chemogenetics: n = 6 and 15. Control group consisted of (i) rAAV1/2 <t>OXTpr-mCherry+CNO,</t> no virus infusion + (ii) saline, or (iii) CNO.
Dreadd Ligand Clozapine N Oxide, supplied by Hello Bio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cno/dreadd+agonist+cno+dihydrochloride++water+soluble+/pm40326013-76-14-25
Average 90 stars, based on 1 article reviews
dreadd ligand clozapine- n- oxide - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Dawley Inc clozapine n-oxide (cno)
a Experimental design for pharmacological <t>and</t> <t>chemogenetic</t> experiments targeting the OXT and AVP systems in isolated and trained (IST) and group-housed (GH) rats. ( AAV adeno-associated DREADD virus infusion into the hypothalamic paraventricular (PVN) and supraoptic (SON) nuclei; AVP arginine vasopressin; arrow=drug infusions; FIT female intruder test, IS social isolation, OXT oxytocin, OXTR-A OXT receptor antagonist, SURG surgery, V1aR-A V1a receptor antagonist, WO wash-out). b i.c.v. infusion of OXT (50 ng/5 µl) increased aggression in GH (two-tailed Student’s t test t (19) = 2.46, p = 0.024), c but decreased aggression in IST females ( t (8) = 2.33, p = 0.048, data corresponds to FIT4 and 6). d i.c.v. infusion of V1aR-A (750 ng/5 µl), but not OXTR-A (750 ng/5 µl), blocked the anti-aggressive effects of OXT in IST females (one-way ANOVA followed by Bonferroni F (3,28) = 10.1, p = 0.001). Also, the V1aR-A alone did not affect aggression. Both, e i.c.v. infusion of OXTR-A ( t (28) = 4.96, p < 0.0001) and f i.c.v. AVP (0.1 or 1 ng/5 µl) reduced total aggressive behavior ( F (3,54) = 7.48, p = 0.0003) in IST rats. g Chemogenetic activation of OXT neurons in the PVN and SON increased aggression only in metestrus-diestrus GH rats (two-way ANOVA, factor treatment: F (1,19) = 3.342, p = 0.083; estrous cycle: F (1,19) = 6.68, p = 0.018; treatment × estrous cycle: F (1,19) = 6.45, p = 0.02). h Confirmation of virus infection in the PVN (right) and SON (left). OXT-neurophysin I staining: green; mCherry (virus): red. Scale bars 300 µm. Data are shown as mean+SEM. * p < 0.05; ** p < 0.01; *** p < 0.0001 vs either vehicle or control; e p < 0.05 vs met-diestrus. OXT: GH: n = 9 and 12; IST: n = 9; AVP: n = 18, 9, and 9, respectively; OXTR-A: n = 14 and 15; combination OXT/OXTR-A/V1aR-A: n = 8, 6, 8, 9, and 7, respectively; chemogenetics: n = 6 and 15. Control group consisted of (i) rAAV1/2 <t>OXTpr-mCherry+CNO,</t> no virus infusion + (ii) saline, or (iii) CNO.
Clozapine N Oxide (Cno), supplied by Dawley Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cno/clozapine+n+oxide++cno+/pm39824647-3-26-5
Average 90 stars, based on 1 article reviews
clozapine n-oxide (cno) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
AK Scientific cno
Locally disrupted S1W E/I balance bidirectionally modulates spectral power locally and in remote sensorimotor areas. (A), Change in power spectral density (∆Power, in decibels) for 1–4 Hz (delta band) GCaMP activity for each pixel in the brain space for each experimental group, comparing three successive 10-min imaging windows after <t>CNO</t> delivery (ON) to a preceding 10-min baseline OFF epoch using equation (1). Data represent group averages (↑PV n = 12, ↓PV n = 12, Control n = 11), quantified within three different ROIs below in C–E. (B), ∆Power spectrogram in S1W LFP, on same decibel scale as A, with frequency on the y-axis (Hz) and time (in minutes) on the x-axis. ∆Power is computed over a continuous 40-min ON epoch after <t>CNO</t> <t>injection,</t> compared to a preceding 10-min OFF epoch. Data represent group averages (↑PV n = 5, ↓PV n = 6, Control n = 5), quantified in F. (C–F) Statistical verification of trends in three ROIs from the GCaMP data—left S1W (C), left M1W (D), and right M1W (E)—as well as LFP data from left S1W (F). Power spectral density is shown in arbitrary units (A.U.). Individual data points represent individual mice, black bars designate mean ± SEM. Significance was calculated by two-way ANOVA with Tukey’s multiple comparison test for each figure panel, comparing both within and between groups. ON-OFF statistical comparisons within group are depicted within each panel, while comparisons between groups are reported in the main text. (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). See also Figure S3 for ∆Power maps for infraslow (0.02–0.1 Hz) GCaMP and oxy-Hb.
Cno, supplied by AK Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cno/cno/pmc07305790-71-18-21
Average 90 stars, based on 1 article reviews
cno - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Enzo Biochem cno chemical
Locally disrupted S1W E/I balance bidirectionally modulates spectral power locally and in remote sensorimotor areas. (A), Change in power spectral density (∆Power, in decibels) for 1–4 Hz (delta band) GCaMP activity for each pixel in the brain space for each experimental group, comparing three successive 10-min imaging windows after <t>CNO</t> delivery (ON) to a preceding 10-min baseline OFF epoch using equation (1). Data represent group averages (↑PV n = 12, ↓PV n = 12, Control n = 11), quantified within three different ROIs below in C–E. (B), ∆Power spectrogram in S1W LFP, on same decibel scale as A, with frequency on the y-axis (Hz) and time (in minutes) on the x-axis. ∆Power is computed over a continuous 40-min ON epoch after <t>CNO</t> <t>injection,</t> compared to a preceding 10-min OFF epoch. Data represent group averages (↑PV n = 5, ↓PV n = 6, Control n = 5), quantified in F. (C–F) Statistical verification of trends in three ROIs from the GCaMP data—left S1W (C), left M1W (D), and right M1W (E)—as well as LFP data from left S1W (F). Power spectral density is shown in arbitrary units (A.U.). Individual data points represent individual mice, black bars designate mean ± SEM. Significance was calculated by two-way ANOVA with Tukey’s multiple comparison test for each figure panel, comparing both within and between groups. ON-OFF statistical comparisons within group are depicted within each panel, while comparisons between groups are reported in the main text. (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). See also Figure S3 for ∆Power maps for infraslow (0.02–0.1 Hz) GCaMP and oxy-Hb.
Cno Chemical, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cno/cno/pm36028570-104-18-22
Average 90 stars, based on 1 article reviews
cno chemical - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Hello Bio Inc cno drug
Locally disrupted S1W E/I balance bidirectionally modulates spectral power locally and in remote sensorimotor areas. (A), Change in power spectral density (∆Power, in decibels) for 1–4 Hz (delta band) GCaMP activity for each pixel in the brain space for each experimental group, comparing three successive 10-min imaging windows after <t>CNO</t> delivery (ON) to a preceding 10-min baseline OFF epoch using equation (1). Data represent group averages (↑PV n = 12, ↓PV n = 12, Control n = 11), quantified within three different ROIs below in C–E. (B), ∆Power spectrogram in S1W LFP, on same decibel scale as A, with frequency on the y-axis (Hz) and time (in minutes) on the x-axis. ∆Power is computed over a continuous 40-min ON epoch after <t>CNO</t> <t>injection,</t> compared to a preceding 10-min OFF epoch. Data represent group averages (↑PV n = 5, ↓PV n = 6, Control n = 5), quantified in F. (C–F) Statistical verification of trends in three ROIs from the GCaMP data—left S1W (C), left M1W (D), and right M1W (E)—as well as LFP data from left S1W (F). Power spectral density is shown in arbitrary units (A.U.). Individual data points represent individual mice, black bars designate mean ± SEM. Significance was calculated by two-way ANOVA with Tukey’s multiple comparison test for each figure panel, comparing both within and between groups. ON-OFF statistical comparisons within group are depicted within each panel, while comparisons between groups are reported in the main text. (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). See also Figure S3 for ∆Power maps for infraslow (0.02–0.1 Hz) GCaMP and oxy-Hb.
Cno Drug, supplied by Hello Bio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cno/cno+chemical/pm40446034-348-26-32
Average 90 stars, based on 1 article reviews
cno drug - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
BrainVTA (Wuhan) Co Ltd ligand cno 3.3 mg/kg
Locally disrupted S1W E/I balance bidirectionally modulates spectral power locally and in remote sensorimotor areas. (A), Change in power spectral density (∆Power, in decibels) for 1–4 Hz (delta band) GCaMP activity for each pixel in the brain space for each experimental group, comparing three successive 10-min imaging windows after <t>CNO</t> delivery (ON) to a preceding 10-min baseline OFF epoch using equation (1). Data represent group averages (↑PV n = 12, ↓PV n = 12, Control n = 11), quantified within three different ROIs below in C–E. (B), ∆Power spectrogram in S1W LFP, on same decibel scale as A, with frequency on the y-axis (Hz) and time (in minutes) on the x-axis. ∆Power is computed over a continuous 40-min ON epoch after <t>CNO</t> <t>injection,</t> compared to a preceding 10-min OFF epoch. Data represent group averages (↑PV n = 5, ↓PV n = 6, Control n = 5), quantified in F. (C–F) Statistical verification of trends in three ROIs from the GCaMP data—left S1W (C), left M1W (D), and right M1W (E)—as well as LFP data from left S1W (F). Power spectral density is shown in arbitrary units (A.U.). Individual data points represent individual mice, black bars designate mean ± SEM. Significance was calculated by two-way ANOVA with Tukey’s multiple comparison test for each figure panel, comparing both within and between groups. ON-OFF statistical comparisons within group are depicted within each panel, while comparisons between groups are reported in the main text. (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). See also Figure S3 for ∆Power maps for infraslow (0.02–0.1 Hz) GCaMP and oxy-Hb.
Ligand Cno 3.3 Mg/Kg, supplied by BrainVTA (Wuhan) Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cno/ligand+cno+3+3+mg+kg/pmc12269989-322-7-11
Average 90 stars, based on 1 article reviews
ligand cno 3.3 mg/kg - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


a Experimental design for pharmacological and chemogenetic experiments targeting the OXT and AVP systems in isolated and trained (IST) and group-housed (GH) rats. ( AAV adeno-associated DREADD virus infusion into the hypothalamic paraventricular (PVN) and supraoptic (SON) nuclei; AVP arginine vasopressin; arrow=drug infusions; FIT female intruder test, IS social isolation, OXT oxytocin, OXTR-A OXT receptor antagonist, SURG surgery, V1aR-A V1a receptor antagonist, WO wash-out). b i.c.v. infusion of OXT (50 ng/5 µl) increased aggression in GH (two-tailed Student’s t test t (19) = 2.46, p = 0.024), c but decreased aggression in IST females ( t (8) = 2.33, p = 0.048, data corresponds to FIT4 and 6). d i.c.v. infusion of V1aR-A (750 ng/5 µl), but not OXTR-A (750 ng/5 µl), blocked the anti-aggressive effects of OXT in IST females (one-way ANOVA followed by Bonferroni F (3,28) = 10.1, p = 0.001). Also, the V1aR-A alone did not affect aggression. Both, e i.c.v. infusion of OXTR-A ( t (28) = 4.96, p < 0.0001) and f i.c.v. AVP (0.1 or 1 ng/5 µl) reduced total aggressive behavior ( F (3,54) = 7.48, p = 0.0003) in IST rats. g Chemogenetic activation of OXT neurons in the PVN and SON increased aggression only in metestrus-diestrus GH rats (two-way ANOVA, factor treatment: F (1,19) = 3.342, p = 0.083; estrous cycle: F (1,19) = 6.68, p = 0.018; treatment × estrous cycle: F (1,19) = 6.45, p = 0.02). h Confirmation of virus infection in the PVN (right) and SON (left). OXT-neurophysin I staining: green; mCherry (virus): red. Scale bars 300 µm. Data are shown as mean+SEM. * p < 0.05; ** p < 0.01; *** p < 0.0001 vs either vehicle or control; e p < 0.05 vs met-diestrus. OXT: GH: n = 9 and 12; IST: n = 9; AVP: n = 18, 9, and 9, respectively; OXTR-A: n = 14 and 15; combination OXT/OXTR-A/V1aR-A: n = 8, 6, 8, 9, and 7, respectively; chemogenetics: n = 6 and 15. Control group consisted of (i) rAAV1/2 OXTpr-mCherry+CNO, no virus infusion + (ii) saline, or (iii) CNO.

Journal: Nature Communications

Article Title: Oxytocin and vasopressin within the ventral and dorsal lateral septum modulate aggression in female rats

doi: 10.1038/s41467-021-23064-5

Figure Lengend Snippet: a Experimental design for pharmacological and chemogenetic experiments targeting the OXT and AVP systems in isolated and trained (IST) and group-housed (GH) rats. ( AAV adeno-associated DREADD virus infusion into the hypothalamic paraventricular (PVN) and supraoptic (SON) nuclei; AVP arginine vasopressin; arrow=drug infusions; FIT female intruder test, IS social isolation, OXT oxytocin, OXTR-A OXT receptor antagonist, SURG surgery, V1aR-A V1a receptor antagonist, WO wash-out). b i.c.v. infusion of OXT (50 ng/5 µl) increased aggression in GH (two-tailed Student’s t test t (19) = 2.46, p = 0.024), c but decreased aggression in IST females ( t (8) = 2.33, p = 0.048, data corresponds to FIT4 and 6). d i.c.v. infusion of V1aR-A (750 ng/5 µl), but not OXTR-A (750 ng/5 µl), blocked the anti-aggressive effects of OXT in IST females (one-way ANOVA followed by Bonferroni F (3,28) = 10.1, p = 0.001). Also, the V1aR-A alone did not affect aggression. Both, e i.c.v. infusion of OXTR-A ( t (28) = 4.96, p < 0.0001) and f i.c.v. AVP (0.1 or 1 ng/5 µl) reduced total aggressive behavior ( F (3,54) = 7.48, p = 0.0003) in IST rats. g Chemogenetic activation of OXT neurons in the PVN and SON increased aggression only in metestrus-diestrus GH rats (two-way ANOVA, factor treatment: F (1,19) = 3.342, p = 0.083; estrous cycle: F (1,19) = 6.68, p = 0.018; treatment × estrous cycle: F (1,19) = 6.45, p = 0.02). h Confirmation of virus infection in the PVN (right) and SON (left). OXT-neurophysin I staining: green; mCherry (virus): red. Scale bars 300 µm. Data are shown as mean+SEM. * p < 0.05; ** p < 0.01; *** p < 0.0001 vs either vehicle or control; e p < 0.05 vs met-diestrus. OXT: GH: n = 9 and 12; IST: n = 9; AVP: n = 18, 9, and 9, respectively; OXTR-A: n = 14 and 15; combination OXT/OXTR-A/V1aR-A: n = 8, 6, 8, 9, and 7, respectively; chemogenetics: n = 6 and 15. Control group consisted of (i) rAAV1/2 OXTpr-mCherry+CNO, no virus infusion + (ii) saline, or (iii) CNO.

Article Snippet: Chemogenetic animals received i.p. infusions either with CNO (HB6149, HelloBio, United Kingdom) or 0.9% saline (1 ml/kg).

Techniques: Isolation, Virus, Two Tailed Test, Activation Assay, Infection, Staining, Control, Saline

Locally disrupted S1W E/I balance bidirectionally modulates spectral power locally and in remote sensorimotor areas. (A), Change in power spectral density (∆Power, in decibels) for 1–4 Hz (delta band) GCaMP activity for each pixel in the brain space for each experimental group, comparing three successive 10-min imaging windows after CNO delivery (ON) to a preceding 10-min baseline OFF epoch using equation (1). Data represent group averages (↑PV n = 12, ↓PV n = 12, Control n = 11), quantified within three different ROIs below in C–E. (B), ∆Power spectrogram in S1W LFP, on same decibel scale as A, with frequency on the y-axis (Hz) and time (in minutes) on the x-axis. ∆Power is computed over a continuous 40-min ON epoch after CNO injection, compared to a preceding 10-min OFF epoch. Data represent group averages (↑PV n = 5, ↓PV n = 6, Control n = 5), quantified in F. (C–F) Statistical verification of trends in three ROIs from the GCaMP data—left S1W (C), left M1W (D), and right M1W (E)—as well as LFP data from left S1W (F). Power spectral density is shown in arbitrary units (A.U.). Individual data points represent individual mice, black bars designate mean ± SEM. Significance was calculated by two-way ANOVA with Tukey’s multiple comparison test for each figure panel, comparing both within and between groups. ON-OFF statistical comparisons within group are depicted within each panel, while comparisons between groups are reported in the main text. (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). See also Figure S3 for ∆Power maps for infraslow (0.02–0.1 Hz) GCaMP and oxy-Hb.

Journal: Cerebral Cortex (New York, NY)

Article Title: Local Perturbations of Cortical Excitability Propagate Differentially Through Large-Scale Functional Networks

doi: 10.1093/cercor/bhz314

Figure Lengend Snippet: Locally disrupted S1W E/I balance bidirectionally modulates spectral power locally and in remote sensorimotor areas. (A), Change in power spectral density (∆Power, in decibels) for 1–4 Hz (delta band) GCaMP activity for each pixel in the brain space for each experimental group, comparing three successive 10-min imaging windows after CNO delivery (ON) to a preceding 10-min baseline OFF epoch using equation (1). Data represent group averages (↑PV n = 12, ↓PV n = 12, Control n = 11), quantified within three different ROIs below in C–E. (B), ∆Power spectrogram in S1W LFP, on same decibel scale as A, with frequency on the y-axis (Hz) and time (in minutes) on the x-axis. ∆Power is computed over a continuous 40-min ON epoch after CNO injection, compared to a preceding 10-min OFF epoch. Data represent group averages (↑PV n = 5, ↓PV n = 6, Control n = 5), quantified in F. (C–F) Statistical verification of trends in three ROIs from the GCaMP data—left S1W (C), left M1W (D), and right M1W (E)—as well as LFP data from left S1W (F). Power spectral density is shown in arbitrary units (A.U.). Individual data points represent individual mice, black bars designate mean ± SEM. Significance was calculated by two-way ANOVA with Tukey’s multiple comparison test for each figure panel, comparing both within and between groups. ON-OFF statistical comparisons within group are depicted within each panel, while comparisons between groups are reported in the main text. (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). See also Figure S3 for ∆Power maps for infraslow (0.02–0.1 Hz) GCaMP and oxy-Hb.

Article Snippet: OFF recordings were collected in the absence of CNO, while ON recordings were conducted after intraperitoneal injection of CNO (1 mg/kg, AKSci).

Techniques: Activity Assay, Imaging, Injection

ON-OFF Changes in S1w ETA activity spread intrahemispherically to M1W but not to the contralateral hemisphere. (A) Illustration of ETA computation. Frames surrounding local peaks above a given threshold (depicted as red line) in the 1–4 Hz GCaMP time series taken from the S1w region were flagged for averaging (run-specific, percentile-based thresholds were computed as described in Methods). Cortex-wide maps corresponding to the flagged frames were averaged to generate a movie of cortical dynamics preceding and succeeding high-amplitude bursts in S1w. (B) Group-averaged GCaMP dynamics surrounding the top 10% of local up-peaks in S1w (centered at 0 s), with DREADDs ON or OFF. (C–E) Average GCaMP fluorescence (∆F′) within four different ROIs at t = 0 s during S1W peaks for each group. Individual data points represent individual mice, black bars designate mean ± SEM, with significance calculated by two-way ANOVA with Tukey’s multiple comparison test (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). Data are shown at baseline (OFF, black) and 30 min after delivery of CNO (ON, magenta). See also Figure S9 to see amplitude distribution of peaks and how they impact FC.

Journal: Cerebral Cortex (New York, NY)

Article Title: Local Perturbations of Cortical Excitability Propagate Differentially Through Large-Scale Functional Networks

doi: 10.1093/cercor/bhz314

Figure Lengend Snippet: ON-OFF Changes in S1w ETA activity spread intrahemispherically to M1W but not to the contralateral hemisphere. (A) Illustration of ETA computation. Frames surrounding local peaks above a given threshold (depicted as red line) in the 1–4 Hz GCaMP time series taken from the S1w region were flagged for averaging (run-specific, percentile-based thresholds were computed as described in Methods). Cortex-wide maps corresponding to the flagged frames were averaged to generate a movie of cortical dynamics preceding and succeeding high-amplitude bursts in S1w. (B) Group-averaged GCaMP dynamics surrounding the top 10% of local up-peaks in S1w (centered at 0 s), with DREADDs ON or OFF. (C–E) Average GCaMP fluorescence (∆F′) within four different ROIs at t = 0 s during S1W peaks for each group. Individual data points represent individual mice, black bars designate mean ± SEM, with significance calculated by two-way ANOVA with Tukey’s multiple comparison test (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). Data are shown at baseline (OFF, black) and 30 min after delivery of CNO (ON, magenta). See also Figure S9 to see amplitude distribution of peaks and how they impact FC.

Article Snippet: OFF recordings were collected in the absence of CNO, while ON recordings were conducted after intraperitoneal injection of CNO (1 mg/kg, AKSci).

Techniques: Activity Assay, Fluorescence

PV-INs modulate S1W excitability to ascending contralateral sensory inputs, but not ipsilateral inputs. (A–B) Group averaged evoked responses to stimulation of the right whiskers (A) and left whiskers (B) (↑PV n = 6, ↓PV n = 6, Control n = 5). Responses are presented as maps of peak GCaMP fluorescence (∆F′) during stimulation, and average stimulation block time series for left and right S1W ROIs. (C,E) Average GCaMP fluorescence within left (L) and right (R) S1W ROIs during right (C) and left (E) whisker stimulation, with data represented as mean ± SEM, and comparisons by two-way ANOVA with Tukey’s multiple comparison test. (D) Time course of CNO effect on right whisker stimulation evoked response, normalized against baseline amplitude, with comparison by two-way ANOVA with Dunnett’s multiple comparison test. Data are shown at baseline (OFF, black) and 30 min after delivery of CNO (ON, magenta).

Journal: Cerebral Cortex (New York, NY)

Article Title: Local Perturbations of Cortical Excitability Propagate Differentially Through Large-Scale Functional Networks

doi: 10.1093/cercor/bhz314

Figure Lengend Snippet: PV-INs modulate S1W excitability to ascending contralateral sensory inputs, but not ipsilateral inputs. (A–B) Group averaged evoked responses to stimulation of the right whiskers (A) and left whiskers (B) (↑PV n = 6, ↓PV n = 6, Control n = 5). Responses are presented as maps of peak GCaMP fluorescence (∆F′) during stimulation, and average stimulation block time series for left and right S1W ROIs. (C,E) Average GCaMP fluorescence within left (L) and right (R) S1W ROIs during right (C) and left (E) whisker stimulation, with data represented as mean ± SEM, and comparisons by two-way ANOVA with Tukey’s multiple comparison test. (D) Time course of CNO effect on right whisker stimulation evoked response, normalized against baseline amplitude, with comparison by two-way ANOVA with Dunnett’s multiple comparison test. Data are shown at baseline (OFF, black) and 30 min after delivery of CNO (ON, magenta).

Article Snippet: OFF recordings were collected in the absence of CNO, while ON recordings were conducted after intraperitoneal injection of CNO (1 mg/kg, AKSci).

Techniques: Fluorescence, Blocking Assay, Whisker Assay

Activating S1W PV-DREADDs induces local changes in activity and excitability. (A,B) Representative time-series of GCaMP fluorescence (∆F′) within the left S1W ROI (A) and separately recorded LFP within S1W averaged over all cortical layers (B) shown for each of the three experimental groups at baseline (OFF, black) and 30 min after delivery of CNO (ON, magenta). See Figures S1 and S2 for quantification of power spectral changes.

Journal: Cerebral Cortex (New York, NY)

Article Title: Local Perturbations of Cortical Excitability Propagate Differentially Through Large-Scale Functional Networks

doi: 10.1093/cercor/bhz314

Figure Lengend Snippet: Activating S1W PV-DREADDs induces local changes in activity and excitability. (A,B) Representative time-series of GCaMP fluorescence (∆F′) within the left S1W ROI (A) and separately recorded LFP within S1W averaged over all cortical layers (B) shown for each of the three experimental groups at baseline (OFF, black) and 30 min after delivery of CNO (ON, magenta). See Figures S1 and S2 for quantification of power spectral changes.

Article Snippet: OFF recordings were collected in the absence of CNO, while ON recordings were conducted after intraperitoneal injection of CNO (1 mg/kg, AKSci).

Techniques: Activity Assay, Fluorescence